IMO Beware of resident oncology experts who think they are never wrong and ignore the funding requirements reality
imo
This is now the equivalent of 5c. - pre consolidation and is only at phase 11 - dosage range trials
We are told there is cash to see out year lol - what about the $20m cash for phase 11b and Cantrixil and collaborations. running costs and wages